Heart Transplant Rejection
📧 Sign up to get email alerts when something new happens for Heart Transplant Rejection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-12-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA label_change · 2019-12-13FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CellCept (mycophenolate mofetil hydrochloride) submitted by Genentech, Inc., influencing labelin…
-
FDA approval · 2019-11-27FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for mycophenolate mofetil submitted by Hikma Pharmaceuticals USA Inc. The approval may involve label…
-
FDA approval · 2019-11-25FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
The FDA approved a supplemental application for mycophenolate mofetil from Concord Biotech Limited.
-
FDA approval · 2019-11-22FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for a generic version of mycophenolate mofetil by Strides Pharma Science Limited. Indications includ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-11-18FDA Approved: TACROLIMUS — Supplemental Application (Jubilant Cadista Pharmaceuticals Inc.)
FDA approved Jubilant Cadista Pharmaceuticals Inc.’s supplemental application for tacrolimus, approving a generic tacrolimus product under a…
-
FDA approval · 2019-10-18FDA Approved: SIROLIMUS — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC for an original application of sirolimus (Rapamune), a generic form of rapamycin, to prevent …
-
FDA approval · 2019-10-04FDA Approved: TACROLIMUS — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for tacrolimus from Quallent Pharmaceuticals Health LLC, granting an additional regulatory action to…
-
FDA approval · 2019-09-17FDA Approved: TACROLIMUS — Supplemental Application (Sandoz Inc.)
The FDA approved a supplemental application for tacrolimus from Sandoz Inc., resulting in changes to the approved product, such as labeling …
-
FDA approval · 2019-06-11FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Prograf (tacrolimus) filed by Astellas Pharma US, Inc. The action updates the labeling to re…
-
FDA approval · 2019-02-27FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) filed by Genentech, resulting in an approved change to the prod…
-
FDA approval · 2019-01-08FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (CONCORD BIOTECH LIMITED)
FDA approved the original application for mycophenolate mofetil (CONCORD BIOTECH LIMITED) for prevention of organ transplant rejection in ki…
-
FDA approval · 2018-08-23FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2018-05-24FDA Approved: PROGRAF — Original Application (Astellas Pharma US, Inc.)
FDA approves PROGRAF (tacrolimus) under the original application for prevention of organ transplant rejection in kidney, liver, and heart tr…
-
FDA approval · 2018-05-24FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for PROGRAF (tacrolimus) submitted by Astellas Pharma US, Inc.
-
FDA approval · 2017-12-18FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Cellcept (mycophenolate mofetil) from Genentech, Inc., authorizing changes to the product’s …
-
FDA approval · 2017-11-30FDA Approved: TACROLIMUS — Original Application (BPI Labs LLC)
The FDA approved an original application for tacrolimus from BPI Labs LLC, authorizing a generic tacrolimus product to prevent organ transpl…
-
FDA approval · 2017-08-23FDA Approved: MYCOPHENOLIC ACID — Original Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s original application for mycophenolic acid, enabling its generic use as an immunosuppressant to preven…
-
CLINICAL_TRIALS research · 2017-02-13Clinical Trial Update: Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation
Clinical trial update exploring the impact of donor and recipient ST2/IL-33 pathway after heart transplantation.
-
FDA approval · 2017-01-06FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)
FDA processed a supplemental approval for ENVARSUS XR (tacrolimus) from Veloxis Pharmaceuticals, potentially expanding its labeling or indic…
-
FDA approval · 2016-10-28FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Endo USA, Inc.)
FDA approves Endo USA, Inc.'s generic mycophenolate mofetil original application (ANDA 203575), enabling its use to prevent organ transplant…
-
FDA approval · 2016-08-01FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for Mycophenolate mofetil from Strides Pharma Science Limited under an ANDA.
-
FDA approval · 2016-08-01FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for the generic drug Mycophenolate mofetil from Strides Pharma Science Limited, finalizing changes t…
-
FDA approval · 2016-06-22FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)
The FDA approved a supplemental application for ENVARSUS XR (tacrolimus) submitted by Veloxis Pharmaceuticals, Inc., adding/updating its ind…
-
FDA approval · 2016-06-07FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)
The FDA approved a supplemental application for ENVARSUS XR (tacrolimus) submitted by Veloxis Pharmaceuticals, Inc. The approval is for the …